NCT05848635

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled ：A Randomized, Parallel Controlled Trial

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 88 (estimated)
• Sponsor: Qianfoshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This randomized, parallel controlled, single blind trial is designed to evaluate the efficacy and safety of hydromorphone versus morphine for perioperative analgesia in lung tumor ablation.

Detailed description

Although the consensus of relevant guidelines and clinical studies recommend the use of opioids for perioperative analgesia in pulmonary tumor ablation surgery, there is a lack of specific analgesic programs for clinical reference. In view of the advantages of clinical application of hydromorphone and the lack of evidence for its application in perioperative analgesia of pulmonary tumor ablation, this study aims to explore the efficacy and safety of hydromorphone in perioperative analgesia of pulmonary tumor ablation, and provide some reference and suggestions for perioperative analgesia of pulmonary tumor ablation.

Conditions

• Pulmonary Nodule
• Ablation

Interventions

Type	Name	Description
DRUG	Hydromorphone Hydrochloride	Drug: Hydromorphone Hydrochloride Hydromorphone hydrochloride injection is used for perioperative lung tumor ablation
DRUG	Morphine hydrochloride	Drug: Morphine Hydrochloride Morphine hydrochloride injection is used for perioperative lung tumor ablation

Timeline

• Start date: 2023-05-01
• Primary completion: 2024-05-01
• Completion: 2024-05-01
• First posted: 2023-05-08
• Last updated: 2023-05-08